epirubicin

基本解釋

Methods The cell line transfected with E1A gene was treated by Epirubicin,Taxotere and 5-fluorouracil respectively.
方法通過(guò)PEI-Fe3O4納米粒介導(dǎo)將E1A基因?qū)肴巳橄侔┘?xì)胞系MCF-7,經(jīng)G418篩選獲得穩(wěn)定表達(dá)E1A的轉(zhuǎn)染細(xì)胞(MCF-7-E1A)。
The standard dose intensity of epirubicin was defined as 20 mg/m2,the dose was 60mg/m2 given every three weeks. Efficacy and toxicity was evaluated.
表阿黴素按標(biāo)準(zhǔn)劑量每3周60mg/m2,劑量強(qiáng)度爲(wèi)20mg/m2,評(píng)估其客觀療傚及毒副作用。
With regard to tumor progression, BCG was also statistically superior to epirubicin (Peto OR=1.70, 95%CI=[1.16, 2.49], P=0.006).
在預(yù)防疾病進(jìn)展方麪;卡介苗同樣優(yōu)於表柔比星(PetoOR=1.;70;95%25CI=[1
Objective To evaluate intravesical epirubicin instillation for preventing the recurrence of superficial bladder tumors after surgical management.
目的探討表阿黴素膀胱灌注防治淺表性膀胱癌術(shù)後複發(fā)的療傚。
Objectives:To study the efficiency and safety of instillation with epirubicin(EPI) to prevent) postoperative recurrence of superficial bladdercancer.
爲(wèi)了觀察法瑪新膀胱灌洗預(yù)防淺表性膀胱癌術(shù)後複發(fā)臨牀療傚。